nevirapine has been researched along with Hepatitis C, Chronic in 15 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy." | 7.72 | Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ( González-Lahoz, J; González-Requena, D; Núñez, M; Soriano, V, 2003) |
| "HAART regimens including nevirapine are associated with faster liver fibrosis progression in HIV-infected patients with chronic hepatitis C." | 7.72 | Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. ( Castellano, V; García-García, JA; Gómez-Mateos, JM; Lozano, F; Macías, J; Merchante, N; Mira, JA; Palacios, RB; Pineda, JA; Sáez, C, 2004) |
| "Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy." | 3.72 | Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ( González-Lahoz, J; González-Requena, D; Núñez, M; Soriano, V, 2003) |
| "HAART regimens including nevirapine are associated with faster liver fibrosis progression in HIV-infected patients with chronic hepatitis C." | 3.72 | Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. ( Castellano, V; García-García, JA; Gómez-Mateos, JM; Lozano, F; Macías, J; Merchante, N; Mira, JA; Palacios, RB; Pineda, JA; Sáez, C, 2004) |
| "A 12 h pharmacokinetic analysis was performed in 18 patients: 7 HIV/HCV-coinfected and 11 HIV-monoinfected." | 1.35 | Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. ( Bertram, N; Fätkenheuer, G; Reichel, C; Rockstroh, JK; Schwarze-Zander, C; Sudhop, T; Vogel, M; Voigt, E; Wasmuth, JC; Wyen, C, 2009) |
| "Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency." | 1.34 | Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. ( Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V, 2007) |
| "Nevirapine plasma levels were measured in 70 HIV-infected patients, 33 of whom developed transaminase elevations." | 1.31 | Liver toxicity caused by nevirapine. ( González de Requena, D; Jiménez-Nácher, I; Núñez, M; Soriano, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (93.33) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vogel, M | 1 |
| Bertram, N | 1 |
| Wasmuth, JC | 1 |
| Wyen, C | 1 |
| Voigt, E | 1 |
| Schwarze-Zander, C | 1 |
| Sudhop, T | 1 |
| Fätkenheuer, G | 1 |
| Rockstroh, JK | 1 |
| Reichel, C | 1 |
| Agbaji, O | 1 |
| Thio, CL | 1 |
| Meloni, S | 1 |
| Graham, C | 1 |
| Muazu, M | 1 |
| Nimzing, L | 1 |
| Idoko, J | 1 |
| Sankalé, JL | 1 |
| Ekong, E | 1 |
| Murphy, R | 1 |
| Kanki, P | 1 |
| Hawkins, C | 1 |
| Núñez, M | 2 |
| González-Requena, D | 1 |
| González-Lahoz, J | 2 |
| Soriano, V | 4 |
| Ena, J | 1 |
| Amador, C | 1 |
| Benito, C | 1 |
| Fenoll, V | 1 |
| Pasquau, F | 1 |
| Weissbrich, B | 1 |
| Langmann, P | 1 |
| Schubert, J | 1 |
| Jassoy, C | 1 |
| Klinker, H | 1 |
| Rodríguez Guardado, A | 1 |
| Maradona Hidalgo, JA | 1 |
| Asensi Alvarez, V | 1 |
| Cartón Sánchez, JA | 1 |
| Macías, J | 1 |
| Castellano, V | 1 |
| Merchante, N | 1 |
| Palacios, RB | 1 |
| Mira, JA | 1 |
| Sáez, C | 1 |
| García-García, JA | 1 |
| Lozano, F | 1 |
| Gómez-Mateos, JM | 1 |
| Pineda, JA | 1 |
| De Requena, DG | 1 |
| Jiménez-Nácher, I | 3 |
| Barreiro, P | 1 |
| Rodríguez-Novoa, S | 1 |
| Labarga, P | 1 |
| Ruiz, A | 1 |
| Martín-Carbonero, L | 1 |
| Phillips, E | 2 |
| Gutiérrez, S | 2 |
| Jahnke, N | 2 |
| Yip, B | 2 |
| Lima, VD | 2 |
| Hogg, RS | 2 |
| Harrigan, PR | 2 |
| Montaner, JS | 2 |
| Raffi, F | 1 |
| Lewden, C | 1 |
| Chêne, G | 1 |
| Hayden, A | 1 |
| García Fernández, D | 1 |
| García-Patos Briones, V | 1 |
| Mollet Sánchez, J | 1 |
| Castells Rodellas, A | 1 |
| González de Requena, D | 1 |
| Dodi, F | 1 |
| Alessandrini, A | 1 |
| Camera, M | 1 |
| Gaffuri, L | 1 |
| Morandi, N | 1 |
| Pagano, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.[NCT01908660] | 192 participants (Actual) | Observational [Patient Registry] | 2007-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nevirapine and Hepatitis C, Chronic
| Article | Year |
|---|---|
[Stevens-Johnson syndrome due to nevirapine].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Hepatitis C, Chronic; HIV-1; Humans; | 2000 |
14 other studies available for nevirapine and Hepatitis C, Chronic
| Article | Year |
|---|---|
Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ne | 2009 |
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induce | 2013 |
Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
Topics: Alanine Transaminase; Anti-HIV Agents; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Che | 2003 |
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
Topics: Adult; Alanine Transaminase; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug I | 2003 |
Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.
Topics: Acute Disease; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic; | 2003 |
[Assessment of nevirapine liver toxicity in patients with HIV and HVC coinfection].
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis C, Chronic; HIV In | 2004 |
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Disease Prog | 2004 |
Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Chemical and Drug Induced | 2005 |
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; F | 2007 |
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru | 2007 |
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infe | 2008 |
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infections; Humans; Nevirapine | 2008 |
Liver toxicity caused by nevirapine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic; HIV Infections; Humans | 2002 |
Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Hepatitis C, Chronic; HIV Infections; Hu | 2002 |